Multiple articles focus on new advances in the study of autoimmune diseases!

In !-- article, we've compiled a number of research results to focus on scientists' new achievements in the field of autoimmune disease research and share them with you! Photo Credit: Frontiers 1 PNAS: Revealing the molecular mechanisms of special lymphocyte populations that promote the development of autoimmune diseases Doi:10.1073/pnas.1920463117, published in the international journal Proceed In a study published in the National Academy of Sciences, scientists from institutions such as the Caroline Institute in Sweden revealed how specific groups of lymphocytes promote the development of autoimmune diseases by giving up their regulatory role in the immune system, and the findings may offer new ideas and hopes for later scientists in developing new treatments for autoimmune diseases.
Autoimmune diseases are the result of an imbalance in the body's immune system that induces the destruction and disruption of many of the mechanisms that normally inhibit the onset of the disease, and now researchers have found that cell groups that normally block autoimmune power may convert their function into disease-promoting outcomes, perhaps as a result of a combination of inflammation and specific stimuli called glycolipids; The lymphocyte population of iNKT cells normally inhibits the production of pathogenic antibodies by its own reactive B cells, but now loses this ability and plays a key role in promoting B cells;
: Identifying targets for new T-cell immunotherapy is expected to help develop new treatments to fight cancer and autoimmune diseases doi:10.1038/s41586-020-2246-4, a study published in the international journal Nature entitled "CRISPR screen in regulatory T cells reveals modulator" In the study, scientists from the University of California and other institutions said that CRISP screening of regulatory T-cells or the expected disclosure of regulatory molecules in Foxp3, one of the key transcription factors that control the development and function of T-cells, is an important advance in Treg immunobiology and opens a "door" for scientists to learn more about the function and mechanism of Treg.
Treg cells are the key cells needed to control the body's immune response and maintain the body's balance, and they are also an important barrier to the body's anti-tumor immunity. Lack of and access to inflammatory properties; a comprehensive and in-depth understanding of the pathfractors that regulate Foxp3 factors may help researchers develop more effective Treg therapies to treat a variety of autoimmune diseases and cancers, and the use of new functional genetic tools can systematically analyze gene regulators that regulate Foxp3 expression.
a deep interpretation of Cell's overview! Challenges, progress and prospects for developing immunologic disease therapies! doi:10.1016/j.cell.2020.03.007 Autoimmune disease is a disease caused by the body's immune system being mis directed to attack the host itself, and more and more people with autoimmune diseases now need it Treatment, which is generally broad and non-disease-specific, and can have many side effects on patients, has made it urgent for researchers to develop precise early interventions, according to an article published in the international journal Cell entitled "Challenges, Progress, In a review article for Prospects of Development to Treat Autoimmune Diseases, scientists from Oxford University and others discuss the challenges, progress and future prospects of researchers developing treatments for autoimmune diseases.
Researchers have now described more than 80 autoimmune diseases, which can be systemic, such as systemic lupus erythematosus, which affects the skin, joints, kidneys and central nervous system; In fact, human leucocyte antigen (HLA) bits are often directly related to increased susceptible risk of autoimmune diseases, and although detailed molecular, immunological, genetic, and clinical studies have provided an in-depth understanding of the molecular mechanisms that induce certain autoimmune diseases, researchers still do not fully understand the drivers of autoimmune diseases in humans, including environmental factors and pathogenesis.
: Control the brakes of the immune system to treat cancer and autoimmune diseases doi:10.1016/j.immuni.2019.10.001, a study published in the international journal Immunity, from Immunologists at St. Jude Children's Research Hospital have found key biological switches for controlling regulatory T-fines, the specialized white blood cells that control the immune system, and researchers say understanding the mechanisms that regulate T-cells offers a range of options for drug development that can lead to treatments for cancer or autoimmune diseases by increasing or suppressing this activity at the right time.
their study, the researchers tracked the molecular mechanism of a biological switch that controls an activated regulatory T cell called mTORC1.
until this, its mechanism had been a mystery; their research showed that the two main regulators of mTORC1 were enzymes called Rag and Rheb.
scientists found that mice lacking Rag or Rheb developed deadly autoimmune diseases, they found the enzyme's key role in activating protective regulatory T cells.
!--/ewebeditor:page--!--ewebeditor:page-title"--Metablol: Dietary intervention strategies or promising to slow the occurrence and progression of inflammatory and autoimmune diseases doi:10.1016/j.cmet 2020.01.006 In a recent study published in the international journal Cell Metablolism, scientists from the Wen'ander Institute and other institutions in the United States found that significantly reducing levels of methionine in the diet may be effective in slowing the occurrence and progression of inflammation and autoimmune disorders in high-risk individuals, such as multiple sclerosis. Many cells in the
body produce methionine, while immune cells responsible for responding to threats such as pathogens do not produce methionine, whereas methionine, which stimulates specific cell types such as T-cells, must be obtained through food intake, although methionine is present in a variety of foods, but animal products such as meat and eggs contain higher levels of methionine.
researcher Russell Jones said methionine is critical to a healthy immune system, and the results suggest that reducing methionine intake can actually slow the activity of disease-inducing immune cells and give patients better prognosis for individuals prone to inflammation and autoimmune disorders such as multiple sclerosis.
photo source: Lars Fugger, et al. Cell, doi:10.1016/j.cell.2020.03.007 ScienceDaily: Love between Prkd2 and Bcl6 controls TFH cell production and is expected to develop In a new study, researchers from the University of Texas Southwestern Medical Center identified the T-cell responsible for controlling follicular helper cells. In the paper, published in the journal Science Immunology, they describe their study of the gene Prkd2 and their understanding of its role in autoimmune diseases.
previous studies have shown that abnormal behavior of TFH cells, a specialized T-cell, can lead to immune response problems, which in turn can lead to autoimmune diseases.
this is because TFH cells help B cells produce antibodies.
the new study, the researchers identified a gene responsible for producing an enzyme that controls TFH activity: Prkd2.
the researchers genetically screened ENU muted mice for their role in the development of autoimmune diseases, the researchers said.
found that mice with mutations in the Prkd2 gene develop hypergammaglobulinemia.
they went on to find that a mutation in functional loss reduced the production of Prkd2W807R enzymes that control the behavior of TFH cells.
without this controlling enzyme, the TFH cell center would form too many birth centers, leading to increased B-cell activity.
this leads to an increase in the production of IgE ---, a condition common in patients with autoimmune diseases.
: New therapeutic candidate antibodies promise to completely treat autoi disease doi:10.1126/sciadv.aax9586 multiple autoimmune diseases often involve pathogenic immunity The production of globulin G (IgG) antibodies, which attack cells and tissues and interact with antigens to form immune complexes, which are particularly dangerous because they can deposit in tissues and promote the further development of autoantibodies, can only be removed or inhibited by invasive methods.
, in a recent study published in the international journal Science Advances, scientists from institutions such as Bregan Women's Hospital found that blocking new crystal fragment receptors (FcRn, neonatal crystallizable fragment receptors) could potentially treat autoimmune diseases by removing IgG and its immune complex.
in preclinical studies and Phase 1 clinical trials, researchers have come up with evidence that extending FcRn's role beyond ingG antibodies from the circulatory system may show its potential in treating autoimmune diseases.
: Scientists hope to develop new treatments to fight autoimmune diseases doi:10.1038/s41590-019-0559-y In a recent study published in the international journal Nature Immunology, from the Cincinnati Children's Medical Center and others The scientists used the study to describe a complete new molecular process in the mouse body that may induce T-cell-driven inflammation and cause different autoimmune diseases; the findings could have implications for treating a variety of diseases, such as multiple sclerosis, type 1 diabetes and inflammatory bowel disease, and are expected to help researchers find new treatments to treat autoimmune diseases.
researcher Chandrashekhar Pasare said: 'We are currently testing the molecular processes found in a variety of human cells, and are working with other researchers to collect cell samples donated from patients with multiple sclerosis, arthritis and other autoimmune diseases.'
Over the past decade, researchers have linked the immune system protein IL-1b (cytokine interlebin 1-beta) to the onset of a variety of autoimmune diseases, and drugs and antibodies that block or suppress IL-1b can be used to effectively control disease symptoms in patients with multiple types of autoimmune diseases.
!--/ewebeditor:page--!--ewebeditor:page title"--9:Sci Adv: The mechanism of drug side effects in patients with autoimmune diseases doi:10.1126/sciadv.aaw9051 rheumatoid arthritis, psoriasis and crohn's disease and other autoimmune diseases plague most groups in the world.
, several new drugs for these diseases are now available.
, however, the use of drugs called TNF inhibitors comes with a risk of serious infection and even cancer.
recently, a team at the University of Michigan School of Medicine may have found the cause of side effects from TNF-a inhibitors.
study, published in the journal Science Advance, reveals previously unknown functions of a tyroblast cell.
are part of the innocular immune network and are the body's first line of defense against threats.
help another type of immune cell called T-cells (which belongs to the adaptive immune system) learn how to respond appropriately to a given bacteria or pathogenic factor.
the main coordinator of the immune response tells other cells in the immune system what to do, and this study shows that these cells have their own form of procedural memory and rely on the TNFa molecule TNFa as part of the system that programs the tyroblades, so they know how to program T cells.
: The highly selective compound BMS-986165 is expected to treat a range of autoimmune diseases and slowness.